Clinical trials · Hartford, CT
Advanced or Metastatic Solid Tumors clinical trials in Hartford
We’re tracking 198 recruiting advanced or metastatic solid tumors studies with a site in or near Hartford — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Hartford
- NCT06343402RecruitingPhase 1
Study of BBO-8520 for advanced KRAS G12C lung cancer
This trial tests a new oral medication called BBO-8520 for advanced lung cancer with a specific gene change (KRAS G12C mutation). It aims to see if the drug is safe and effective, and may be combined with another drug (pembrolizumab) in some groups.
New Haven, ConnecticutAges 18 years+ - NCT07172256RecruitingPhase 2
CUE-101 plus pembrolizumab for HPV+ throat cancer
This trial tests a new drug called CUE-101 combined with a standard immunotherapy (pembrolizumab) for people with HPV-16 positive head and neck cancer that cannot be removed with surgery. The goal is to see if this combination can shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT03463954Recruiting
Laser treatment trial for small breast tumors
This trial tests a focused laser treatment (Novilase®) to destroy small, cancerous breast tumors while aiming to work with standard care. It may help people who have an early, localized tumor that can be clearly seen on imaging so doctors can guide the laser safely.
New Haven, ConnecticutAges 18 years+ - NCT03486873RecruitingPhase 3
Study extension for people on pembrolizumab, testing long-term safety
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
New Haven, ConnecticutAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
New Haven, ConnecticutAges 18 years+ - NCT07197827RecruitingPhase 1/Phase 2
YL242 for advanced solid tumors study
This trial tests a new drug called YL242 in people with advanced solid tumors that have not responded to prior treatment or have not been treated yet. It looks at safety, how well the drug works, and includes different groups based on cancer type and prior therapy.
New Haven, ConnecticutAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune disease
This trial tests whether the immunotherapy drug nivolumab can safely treat advanced cancer in people who also have an autoimmune disease like rheumatoid arthritis, lupus, or multiple sclerosis. It aims to find out if the drug may help control cancer while managing their autoimmune condition.
New Haven, ConnecticutAges 18 years+ - NCT06982521RecruitingPhase 3
Comparing two drug combinations for advanced breast cancer
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
New Haven, ConnecticutAges 18 years+ - NCT07456046RecruitingPhase 1
Study of D3S-003 for advanced solid tumors with KRAS G12D mutation
This trial tests a new medicine called D3S-003 in people whose cancer has a specific change (mutation) known as KRAS G12D. The medicine aims to target and attack cancer cells with this mutation. It may be an option if standard treatments have stopped working or are not available.
New Haven, ConnecticutAges 18 years+ - NCT06311214RecruitingPhase 2
Personalized ADC therapy for advanced solid tumors
This trial tests personalized antibody-drug conjugates (ADCs) for advanced solid tumors. It looks for specific proteins on your tumor cells to match you with a treatment that targets them directly.
New Haven, ConnecticutAges 18 years+ - NCT07215910RecruitingPhase 3
Testing vorasidenib with temozolomide after radiation for advanced brain cancer
This trial tests whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of advanced brain cancer called IDH-mutant astrocytoma. It is for patients who have not had previous treatments like chemotherapy or radiation and whose tumors have certain genetic features.
New Haven, ConnecticutAges 12 years+ - NCT07362888RecruitingPhase 1
Testing a new drug ADCE-B05 for advanced solid tumors
This trial tests a new investigational drug called ADCE-B05 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
New Haven, ConnecticutAges 18 years+ - NCT05125016RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer after standard treatments
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
New Haven, ConnecticutAges 18 years+ - NCT06994806RecruitingPhase 1
KQB168 for advanced solid tumors post immunotherapy
This trial tests a new oral drug (KQB168) given alone or with other medicines for people with advanced solid tumors that have not responded to immunotherapy. The goal is to see if it is safe and can help shrink or slow the growth of cancer.
New Haven, ConnecticutAges 18 years+ - NCT05280314RecruitingPhase 2
Immunotherapy before and after surgery for stage III melanoma or throat cancer
This trial tests two immunotherapy medicines given before surgery and again after surgery to help control the cancer and improve outcomes. It studies people with resectable (operable) stage III melanoma or certain stage III/IVA throat cancers.
New Haven, ConnecticutAges 18 years+ - NCT07011719RecruitingPhase 3
Kidney cancer trial: new combo vs. cabozantinib alone
This trial tests a new drug (casdatifan) combined with cabozantinib for advanced clear cell kidney cancer, comparing it to cabozantinib alone. It's for people who haven't taken these specific medicines before and are still in fairly good health.
New Haven, ConnecticutAges 18 years+ - NCT05382559RecruitingPhase 1
Study drug for advanced cancers with KRAS G12D mutation
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
New Haven, ConnecticutAges 18 years+ - NCT05684965RecruitingPhase 1/Phase 2
Study drug for advanced solid cancers after standard treatments
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
New Haven, ConnecticutAges 18 years+ - NCT06963905RecruitingPhase 1/Phase 2
Testing a combination drug for triple-negative breast cancer
This trial is testing a combination of three drugs—sacituzumab govitecan, nivolumab, and relatlimab—for people with metastatic triple-negative breast cancer that has progressed after at least one prior therapy. You may qualify if you have this specific type of breast cancer and have received certain prior treatments.
New Haven, ConnecticutAges 18 years+ - NCT06458712RecruitingPhase 1
Testing a new drug for advanced cancers with gene changes
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT05768139RecruitingPhase 1/Phase 2
Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
New Haven, ConnecticutAges 18 years+ - NCT03151629Recruiting
Registry for men with advanced prostate cancer
This study is a worldwide registry that collects health information from men with advanced prostate cancer. It may help researchers better understand disease patterns and outcomes, which can guide future treatments.
New Haven, ConnecticutAges 21 years+ - NCT06445062RecruitingPhase 1/Phase 2
RAS-targeting drugs for gastrointestinal cancers
This trial tests new drugs that target a specific genetic change (RAS) in gastrointestinal cancers like pancreatic and colorectal cancer. The goal is to see if these drugs can shrink or slow down the cancer.
New Haven, ConnecticutAges 18 years+ - NCT07042100RecruitingPhase 1
Safety study of SBO-154 for advanced solid tumors
This trial tests a new drug called SBO-154 to see if it is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. It may be an option if you have few or no other treatment choices.
New Haven, ConnecticutAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens near Hartford, CT
We’ll email you when one opens near Hartford, CT — at most once a week, no account needed, unsubscribe anytime.
Advanced or Metastatic Solid Tumors trials in other cities
Where these studies are running near Hartford
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Yale University · 10 studies
- Yale-New Haven Hospital (including Smilow Cancer Hospital and Saint Raphael Campus) · 3 studies
- D3 Bio Investigative Site 1404
- Exelixis Clinical Site
- Research Site
- Smilow Cancer Hospital at Yale-New Haven
- US-201
- Yale Cancer Center
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting advanced or metastatic solid tumors studies in Connecticut.
Common questions
- Are there advanced or metastatic solid tumors clinical trials near Hartford?
- Yes. We're currently tracking 198 recruiting advanced or metastatic solid tumors studies with a site near Hartford, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study near Hartford?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Hartford to take part?
- Not necessarily. These studies have a site near Hartford, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open near Hartford regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.